Modernatx, Inc.

This study tests an experimental mRNA vaccine (mRNA-1982) designed to prevent Lyme disease, which is spread by tick bites. About 350 healthy adults aged 18 to 70 will receive either the vaccine or a placebo to check for safety and immune response. The goal is to find the best dos…

This large phase 3 trial is testing an experimental mRNA vaccine (mRNA-1018-H5) designed to protect against H5N1 pandemic influenza. Around 4,000 healthy adults aged 18 and older will receive two doses of the vaccine or a placebo. Researchers will measure immune responses and mon…

This study tests several updated mRNA COVID-19 vaccines designed to target new variants of the virus. About 1,100 adults and children with certain risk factors will receive one of the vaccines to see how well it boosts immunity and how safe it is. The goal is to ensure vaccines r…

This early-stage trial is testing an mRNA vaccine called mRNA-1189 to see if it is safe and triggers an immune response against Epstein-Barr virus (EBV). EBV is a common virus that can cause mononucleosis and is linked to certain cancers. The study involves 120 healthy adults age…

This study tests a new drug called mRNA-2808 in people with multiple myeloma that has returned or not responded to standard treatments. The drug is given through a vein and aims to control the cancer. The trial will check for side effects and measure how well the drug works. Abou…

This study tests an experimental mRNA therapy called mRNA-4359, given alone or with standard immunotherapy drugs, in people with advanced solid tumors (like melanoma, lung cancer, or colorectal cancer). The main goals are to find a safe dose and see if the treatment can shrink tu…

This Phase 2 trial tests an experimental mRNA therapy called mRNA-1195 in 180 adults aged 18 to 55 with relapsing multiple sclerosis. Participants receive either the mRNA shot or a placebo, and researchers monitor safety and measure new brain lesions on MRI scans over about 2.5 y…

This study looks at the long-term safety of an experimental medicine called mRNA-3927 for people with propionic acidemia, a rare genetic disorder that prevents the body from breaking down certain proteins and fats. About 50 participants who were in an earlier study will continue …

This study tests an experimental mRNA therapy called mRNA-3927 for propionic acidemia, a rare genetic disorder that causes dangerous metabolic crises. The trial involves about 77 participants of all ages, starting with older children and adults. Researchers will check safety, fin…

This study is testing the long-term safety of an mRNA therapy called mRNA-3705 in people with methylmalonic acidemia (MMA), a rare genetic disorder that prevents the body from breaking down certain proteins and fats. Participants have already been in earlier studies of this drug.…

This study is not testing any new drug or treatment. Instead, researchers will look back at medical records of 60 people with propionic acidemia, a rare genetic disorder that affects how the body breaks down certain proteins and fats. The goal is to better understand the disease,…